Imiquimod

CHF 55.00
In stock
AG-CR1-3569-M100100 mgCHF 55.00
AG-CR1-3569-M250250 mgCHF 110.00
More Information
Product Details
Synonyms 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline; S26308; R-837
Product Type Chemical
Properties
Formula

C14H16N4

MW 240.3
CAS 99011-02-6
Purity Chemicals ≥98%
Appearance White to off-white powder.
Solubility Soluble in DMSO or dimethylformamide. Insoluble in ethanol. Slightly soluble in water.
Identity Determined by IR.
InChi Key DOUYETYNHWVLEO-UHFFFAOYSA-N
Smiles CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Stock solutions are stable for at least 3 months when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Immune response modulator [1, 2].
  • Anti-inflammatory [3, 5].
  • TLR7 agonist [3, 5].
  • Stimulates proinflammatory cytokine production interferon-α (IFN-α), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) and activates NF-κB [3, 5].
  • Caspase-3 activator that directly induces procaspase-3 cleavage [4].
  • Anti-cancer compound [4, 9].
  • Apoptosis inducer [4, 9].
  • Antiproliferative, independent of immune system activation or function.
  • Antiviral [10] and anti-angiogenic [6, 7, 8].
  • Approved treatment for external genital warts caused by human papillomavirus infection [10].
Product References
  1. Imiquimod applied topically: a novel immune response modifier and new class of drug: R.L. Miller, et al.; Int. J. Immunopharmacol. 21, 1 (1999)
  2. A review of the applications of imiquimod: a novel immune response modifier: T.A. Syed, et al.; Exp. Opin. Pharmacother. 2, 877 (2001)
  3. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway: H. Hemmi, et al.; Nat. Immunol. 3, 196 (2002)
  4. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod: M. Schon, et al.; J. Natl. Cancer Inst. 95, 1138 (2003)
  5. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7: J. Lee, et al.; PNAS 100, 6646 (2003)
  6. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases: C. Hesling, et al.; Br. J. Dermatol. 150, 761 (2004)
  7. Imiquimod as an antiangiogenic agent: V.W. Li, et al.; J. Drugs Dermatol. 4, 708 (2005)
  8. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis: S. Majewski, et al.; Int. J. Dermatol. 44, 14 (2005)
  9. The antitumoral mode of action of imiquimod and other imidazoquinolines: M. Schon & M.P. Schon; Curr. Med. Chem. 14, 681 (2007)
  10. The pharmacology of endosomal TLR agonists in viral disease: D.R. Averett, et al.; Biochem. Soc. Trans. 35, 1468 (2007)
  11. TLR7 agonists display potent antiviral effects against norovirus infection via innate stimulation: D.E. Tuipulotu, et al.; Antimicrob. Agents Chemother., ahead of print (2018)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.